Produção Nacional
Revisado por pares
Novel formulation approaches for synergistic codelivery based on lipid nanocarriers
2023; Future Medicine; Volume: 18; Issue: 7 Linguagem: Inglês
10.2217/nnm-2023-0085
ISSN1748-6963
AutoresEduardo Burgarelli Lages, Gabriel Silva Marques Borges, Lucas Antônio Miranda Ferreira,
Tópico(s)Advanced biosensing and bioanalysis techniques
ResumoNanomedicineAhead of Print EditorialNovel formulation approaches for synergistic codelivery based on lipid nanocarriersEduardo Burgarelli Lages‡, Gabriel Silva Marques Borges‡ & Lucas Antônio Miranda FerreiraEduardo Burgarelli Lages‡ *Author for correspondence: Tel.: +55 313 409 6961; E-mail Address: eduardoburgarelli@ufmg.brhttps://orcid.org/0000-0002-2458-6021Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, CEP 31270-901, Minas Gerais, Brazil, Gabriel Silva Marques Borges‡ https://orcid.org/0000-0002-7360-8231Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, CEP 31270-901, Minas Gerais, Brazil & Lucas Antônio Miranda Ferreira https://orcid.org/0000-0003-2474-5536Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, CEP 31270-901, Minas Gerais, BrazilPublished Online:11 May 2023https://doi.org/10.2217/nnm-2023-0085AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: cancercoencapsulationcombination therapynanoparticlessynergismReferences1. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58(3), 621–681 (2006).Crossref, Medline, CAS, Google Scholar2. Franco MS, Oliveira MC. Ratiometric drug delivery using non-liposomal nanocarriers as an approach to increase efficacy and safety of combination chemotherapy. Biomed. Pharmacother. 96, 584–595 (2017).Crossref, Medline, CAS, Google Scholar3. Zhang RX, Wong HL, Xue HY et al. Nanomedicine of synergistic drug combinations for cancer therapy–strategies and perspectives. J. Control. Rel. 240, 489–503 (2016).Crossref, Medline, CAS, Google Scholar4. Alfayez M, Kantarjian H, Kadia T et al. CPX-351 (vyxeos) in AML. Leuk. Lymphoma 61(2), 288–297 (2020).Crossref, Medline, CAS, Google Scholar5. Fujita D. Challenges to large molecular encapsulation. Pure Appl. Chem. 86(1), 3–11 (2014).Crossref, CAS, Google Scholar6. Layre AM, Gref R, Richard J et al. Nanoencapsulation of a crystalline drug. Int. J. Pharm. 298(2), 323–327 (2005).Crossref, Medline, CAS, Google Scholar7. Bhattacharjee S. Craft of co-encapsulation in nanomedicine: a struggle to achieve synergy through reciprocity. ACS Pharmacol. Transl. Sci. 5(5), 278–298 (2022).Crossref, Medline, CAS, Google Scholar8. Gordillo-Galeano A, Mora-Huertas CE. Solid lipid nanoparticles and nanostructured lipid carriers: a review emphasizing on particle structure and drug release. Eur. J. Pharm. Biopharm. 133, 285–308 (2018).Crossref, Medline, CAS, Google Scholar9. Abet V, Filace F, Recio J et al. Prodrug approach: an overview of recent cases. Eur. J. Med. Chem. 127, 810–827 (2017).Crossref, Medline, CAS, Google Scholar10. Yu J, Wang Y, Zhou S et al. Remote loading paclitaxel–doxorubicin prodrug into liposomes for cancer combination therapy. Acta Pharm. Sin. B 10(9), 1730–1740 (2020).Crossref, Medline, CAS, Google Scholar11. Ni S, Qiu L, Zhang G et al. Lymph cancer chemotherapy: delivery of doxorubicin-gemcitabine prodrug and vincristine by nanostructured lipid carriers. Int. J. Nanomed. 12, 1565–1576 (2017).Crossref, Medline, CAS, Google Scholar12. Gupta P, Neupane YR, Parvez S et al. Recent advances in targeted nanotherapeutic approaches for breast cancer management. Nanomedicine 16(29), 2605–2631 (2021).Link, CAS, Google Scholar13. Guo S, Zhang Y, Wu Z et al. Synergistic combination therapy of lung cancer: cetuximab functionalized nanostructured lipid carriers for the co-delivery of paclitaxel and 5-demethylnobiletin. Biomed. Pharmacother. 118, 109225 (2019).Crossref, Medline, CAS, Google Scholar14. Mazzotta E, Orlando C, Muzzalupo R. New nanomaterials with intrinsic antioxidant activity by surface functionalization of niosomes with natural phenolic acids. Pharmaceutics 13(6), 766 (2021).Crossref, Medline, CAS, Google Scholar15. Lages EB, Fernandes RS, Silva JO et al. Co-delivery of doxorubicin, docosahexaenoic acid, and α-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicity. Biomed. Pharmacother. 132, 110876 (2020).Crossref, Medline, CAS, Google Scholar16. Carvalho FV, Ribeiro LNM, Moura LD et al. Docetaxel loaded in copaiba oil-nanostructured lipid carriers as a promising DDS for breast cancer treatment. Molecules 27(24), 8838 (2022).Crossref, Medline, CAS, Google Scholar17. Kalhapure RS, Mocktar C, Sikwal DR et al. Ion pairing with linoleic acid simultaneously enhances encapsulation efficiency and antibacterial activity of vancomycin in solid lipid nanoparticles. Colloids Surf. B 117, 303–311 (2014).Crossref, Medline, CAS, Google Scholar18. Oliveira MS, Mussi SV, Gomes DA et al. α-Tocopherol succinate improves encapsulation and anticancer activity of doxorubicin loaded in solid lipid nanoparticles. Colloids Surf. B 140, 246–253 (2016).Crossref, Medline, CAS, Google Scholar19. Boratto FA, Franco MS, Barros ALB et al. Alpha-tocopheryl succinate improves encapsulation, pH-sensitivity, antitumor activity and reduces toxicity of doxorubicin-loaded liposomes. Eur. J. Pharm. Sci. 144, 105205 (2020).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Ahead of Print STAY CONNECTED Metrics Downloaded 15 times History Received 21 March 2023 Accepted 6 April 2023 Published online 11 May 2023 Information© 2023 Future Medicine LtdKeywordscancercoencapsulationcombination therapynanoparticlessynergismFinancial & competing interests disclosureThis work was supported by the Brazilian agencies Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download
Referência(s)